Although mu opioid (MOP) receptor agonists are the most commonly used analgesics for the
treatment of moderate to severe pain in the clinic, the side effects of MOP agonists such as …

As clinical use of currently available opioid analgesics is often impeded by dose-limiting
adverse effects, such as abuse liability and respiratory depression, new approaches have …

Despite similar distribution patterns and intracellular events observed in the
nociceptin/orphanin FQ peptide (NOP) receptor and other opioid receptors, NOP receptor …

Misuse of prescription opioids, opioid addiction, and overdose underscore the urgent need
for developing addiction-free effective medications for treating severe pain. Mu opioid …

The nociceptin/orphanin FQ peptide (NOP) receptor-related ligands have been
demonstrated in preclinical studies for several therapeutic applications. This article …

The NOP receptor (nociceptin/orphanin FQ opioid peptide receptor) is the most recently
discovered member of the opioid receptor family and, together with its endogenous ligand …

Following the identification of the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) as an
endogenous ligand for the NOP receptor, ample evidence has revealed unique functional …

The nociceptin receptor (NOPr), a member of the opioid receptor family, is a target for the
treatment of pain and drug abuse. Nociceptin/orphanin FQ (N/OFQ), the endogenous …

Behavioral effects of a nonpeptidic NOP (nociceptin/orphanin FQ Peptide) receptor agonist,
Ro 64-6198, have not been studied in primate species. The aim of the study was to verify the …

In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its
ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in …